MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Lighting the Torch: Dating the Most Common Recent Ancestor of the PINK1 p.L347P Variant Linked to Parkinson’s Disease in Pacific Populations

C. Buchanan, A H. Tan, A. Ahmad-Annuar, S-Y. Lim, YW. Tay, T. Siddique, J. Donnelly, G. Monahan, M. Bruno, R. Minster, S. Viali, F. Fa'Alau, C. Puli'Uvea, N. Edwards, G. Vailahi, R. Roxburgh (Auckland, New Zealand)

Meeting: 2025 International Congress

Keywords: Gait disorders: Genetics, Parkinson’s, PTEN induced kinase-1(PINK1)

Category: Education, History, Disparities (Other)

Objective: To determine the generational age of the most recent common ancestor (MRCA) of patients homozygous for PINK1 p.L347P, to 1) Test the hypothesis that PINK1 EOPD in the Pacific resulted from a founder effect; 2) Provide an origin story for patients.

Background: Mutations in the PINK1 gene cause autosomal recessive early-onset Parkinson’s disease (EOPD)1, with a global prevalence of 1% to 7% in (largely European) EOPD patients1,2,3. To date our studies have shown that a pathogenic p.L347P PINK1 variant that is not found in European, African or Chinese populations, is the cause of over 70% of EOPD in Pacific patients in New Zealand. This variant has only been reported in populations across the Pacific3,4,5,6 – probably due to a founder effect – but to date there is no evidence that it impacts New Zealand Māori.

Method: Twenty samples, homozygous for p.L347P, of Malay, Chamorro, Tokelauan, Samoan, and Tongan ancestries were genotyped on the Infinium Global Diversity chip v1.0.

HapMap markers associated with the p.L347P variant were defined by continuous sharing of homozygosity. Common Haplotype lengths were used to calculate generational age of the MRCA using the Genetic Mutation Age Estimator Tool7,8.

Results: Assuming a correlated genealogy, the p.L347P mutation arose 106.3 generations ago, (CI=9.6-204.8). Depending on the time span used for generation age (20 or 25 years), this equates to a mutation age of 2120-2650 years before present (YBP; CI=200-5125 years).

Conclusion: Our results confirm the hypothesis that p.L347P arose from a founder ancestor who lived approximately 2120-2650 years ago, whose descendants migrated across the western Pacific and thus provides patients with an origin story for their Parkinson’s disease. It is postulated that migration routes from maritime South East Asia into the Pacific occurred 3000-3500 YBP, with subsequent migration into Eastern Polynesia occurring 730-1200 YBP9. The dating suggests that p.L347P arose after the initial Western Polynesian migration. It is possible that the variant didn’t reach deep into Polynesia early enough for it to be carried on the Eastern Pacific migration explaining the low rates in Eastern Polynesian peoples (including NZ Māori). Future work is underway to refine these findings and further explore PINK1 genetics in Pacific populations.

References: 1. Valente EM, Salvi S, Ialongo T, et al.( 2004) PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol;56(3):336-341.
2. Healy DG, Abou-Sleiman PM, Gibson JM, et al. (2004) PINK1 (PARK6) associated Parkinson disease in Ireland. Neurology;63(8):1486-1488.
3. Rogaeva E, Johnson J, Lang AE, et al.( 2004) Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol;61(12):1898-1904.
4. Patel SG, Buchanan CM, Mulroy E, et al. (2021) Potential PINK1 founder effect in Polynesia causing early-onset Parkinson’s disease. Mov Disord;36(9):2199-2200.
5. Tan AH, Lohmann K, Tay YW, et al. (2020) PINK1 p.Leu347Pro mutations in Malays: Prevalence and illustrative cases. Parkinsonism Relat Disord;79:34-39.
6. Steele JC, Guella I, Szu-Tu C, et al. (2015) Defining neurodegeneration on Guam by targeted genomic sequencing. Ann Neurol77(3):458-468.
7. Gandolfo LC, Bahlo M, Speed TP (2014) Dating rare mutations from small samples with dense marker data. Genetics 197, 1315-1327.
8. https://shiny.wehi.edu.au/rafehi.h/mutation-dating/
9. Matisoo-Smith E (2015) Ancient DNA and the human settlement of the Pacific: a review. J Hum Evol 79: 93-104.

To cite this abstract in AMA style:

C. Buchanan, A H. Tan, A. Ahmad-Annuar, S-Y. Lim, YW. Tay, T. Siddique, J. Donnelly, G. Monahan, M. Bruno, R. Minster, S. Viali, F. Fa'Alau, C. Puli'Uvea, N. Edwards, G. Vailahi, R. Roxburgh. Lighting the Torch: Dating the Most Common Recent Ancestor of the PINK1 p.L347P Variant Linked to Parkinson’s Disease in Pacific Populations [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/lighting-the-torch-dating-the-most-common-recent-ancestor-of-the-pink1-p-l347p-variant-linked-to-parkinsons-disease-in-pacific-populations/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/lighting-the-torch-dating-the-most-common-recent-ancestor-of-the-pink1-p-l347p-variant-linked-to-parkinsons-disease-in-pacific-populations/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley